All treatments
Treatment
Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Open-label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older
This study is looking at the long-term safety and effectiveness of a new three-in-one medicine called Kaftrio (also known as Elexacaftor/Tezacaftor/Ivacaftor) for people aged 2 and older with Cystic Fibrosis. Researchers want to see how well it works and if it has any side effects over time.
For: Cystic FibrosisGermany - AuthorisedTherapeutic use (Phase IV)
A low-intervention prospective-retrospective study to evaluate the pharmacokinetics of elexacaftor/tezacaftor/ivacaftor combination in a Cystic Fibrosis population
This study looks at how a cystic fibrosis medicine called Kaftrio works in the body. Researchers want to understand how much of the medicine gets into the blood and how long it stays there, to help make sure patients are getting the most benefit.
For: Cystic FibrosisItaly